Our biotech client was looking to develop and commercialize large, CNS gene delivery platform based on recently developed intellectual property. LSC aided the C-suite’s understanding of investment requirements and critical money flows by aligning financial requirements to developmental checkpoints. LSC developed a long-term business model, including identification of critical investment checkpoints necessary to sustain the business. Further, LSC evaluated two leading indications to understand NPV and impact on client’s overall valuation. The client was able to use LSC’s work in the process to secure nearly €70M in a Series A funding round.